A Study of XW003 Injection in Chinese Adolescents With Obesity

Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Study ID
NCT07143227
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - 18 Years
Healthy Volunteers
Accepted

Interventions

  • XW003 injection — DRUG
    Subcutaneous injection
  • placebo with matching volume — DRUG
    Subcutaneous injection

Study Details

The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity

Key Dates

Start date
Aug 25, 2025
Status verified
Aug 2025
Primary completion
Apr 18, 2026
Completion
Apr 18, 2026

Study Design

Enrollment
48 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: XW003 Dose 1
    once weekly
  • Experimental: XW003 Dose 2
    once weekly
  • Experimental: XW003 Dose 3
    once weekly
  • Placebo Comparator: placebo
    once weekly

Primary Outcome Measure

Number and severity of adverse events [ Time Frame: week 20 ]

Related Studies